Literature DB >> 16549687

Subtotal parathyroidectomy as an adequate treatment for primary hyperparathyroidism in multiple endocrine neoplasia type 1.

Johnathan G H Hubbard1, Frederic Sebag, Sylvie Maweja, Jean-Francois Henry.   

Abstract

HYPOTHESIS: The most appropriate surgical approach for hyperparathyroidism (HPT) in multiple endocrine neoplasia type 1 remains controversial. It has been advocated that reoperations for recurrent disease are easier to perform after total parathyroidectomy (TP) with autotransplantation than after subtotal parathyroidectomy (SP). In view of our large experience in patients with secondary HPT for whom TP with autotransplantation did not simplify reoperations, SP remains our preferred treatment for patients with HPT and multiple endocrine neoplasia type 1.
DESIGN: Retrospective cohort study.
SETTING: Tertiary referral medical center. PATIENTS: A total of 29 consecutive patients (22 women, 7 men; mean age, 42.2 years) with multiple endocrine neoplasia type 1 who underwent definitive cervical exploration for HPT. MAIN OUTCOME MEASURES: Temporary and permanent hypocalcemia, pattern of parathyroid disease, and sites and timing of recurrent HPT. Definitive primary surgery included SP in 21 patients, TP with autotransplantation in 4 patients, and less-than-subtotal parathyroidectomy in 4 selected patients.
RESULTS: The mean follow-up was 88.5 months (range, 8-285 months). Four patients died during follow-up; 2 of these deaths were related to multiple endocrine neoplasia. No patients had persistent HPT. Temporary hypocalcemia occurred in 12 SP cases (57%), 4 TP with autotransplantation cases (100%), and 0 less-than-subtotal parathyroidectomy cases. Permanent hypocalcemia requiring long-term treatment occurred in 2 SP cases (10%), 1 TP with autotransplantation case (25%), and 0 less-than-subtotal parathyroidectomy cases. Four patients developed recurrent disease, including 1 with SP, 2 with TP with autotransplantation, and 1 with less-than-subtotal parathyroidectomy at 57 months, 197 and 180 months, and 164 months, respectively, representing 14% of all of the patients and 43% of patients with more than 10 years of follow-up.
CONCLUSIONS: Recurrent HPT occurs many years after definitive primary surgery (median, 14.3 years). Surgical treatment should therefore aim to minimize the risk of permanent hypocalcemia and facilitate future surgery. When correctly performed, SP fulfills these objectives.

Entities:  

Mesh:

Year:  2006        PMID: 16549687     DOI: 10.1001/archsurg.141.3.235

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  16 in total

1.  Impact of "Tailored" Parathyroidectomy for Treatment of Primary Hyperparathyroidism in Patients with Multiple Endocrine Neoplasia Type 1.

Authors:  Kiyomi Horiuchi; Momoko Sakurai; Kento Haniu; Erin Nagai; Hiroki Tokumitsu; Yusaku Yoshida; Yoko Omi; Akiko Sakamoto; Takahiro Okamoto
Journal:  World J Surg       Date:  2018-06       Impact factor: 3.352

2.  Causes and treatment of recurrent hyperparathyroidism after subtotal parathyroidectomy in the presence of multiple endocrine neoplasia 1.

Authors:  Maria D Balsalobre Salmeron; Jose Manuel Rodriguez Gonzalez; Joan Sancho Insenser; Joan Sancho Fornos; Albert Goday; Nuria Maria Torregrosa Perez; Antonio Rios Zambudio; Pascual Parrilla Paricio; Antonio Sitges Serra
Journal:  World J Surg       Date:  2010-06       Impact factor: 3.352

Review 3.  The optimal surgical treatment for primary hyperparathyroidism in MEN1 patients: a systematic review.

Authors:  Jennifer M J Schreinemakers; Carolina R C Pieterman; Anouk Scholten; Menno R Vriens; Gerlof D Valk; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2011-09       Impact factor: 3.352

Review 4.  Care for patients with multiple endocrine neoplasia type 1: the current evidence base.

Authors:  C R C Pieterman; M R Vriens; K M A Dreijerink; R B van der Luijt; G D Valk
Journal:  Fam Cancer       Date:  2011-03       Impact factor: 2.375

Review 5.  Bilateral neck exploration in primary hyperparathyroidism--when is it selected and how is it performed?

Authors:  Jacob Moalem; Marlon Guerrero; Electron Kebebew
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

Review 6.  Familial parathyroid tumors: diagnosis and management.

Authors:  Peter Stålberg; Tobias Carling
Journal:  World J Surg       Date:  2009-11       Impact factor: 3.352

7.  Diagnostic, therapeutic and healthcare management protocols in parathyroid surgery: II Consensus Conference of the Italian Association of Endocrine Surgery Units (U.E.C. CLUB).

Authors:  L Rosato; M Raffaelli; R Bellantone; A Pontecorvi; N Avenia; M Boniardi; M L Brandi; F Cetani; M G Chiofalo; G Conzo; M De Palma; G Gasparri; A Giordano; N Innaro; E Leopaldi; G Mariani; C Marcocci; P Marini; P Miccoli; P Nasi; F Pacini; R Paragliola; M R Pelizzo; M Testini; G De Toma
Journal:  J Endocrinol Invest       Date:  2014-01-09       Impact factor: 4.256

8.  Prospective study of surgery for primary hyperparathyroidism (HPT) in multiple endocrine neoplasia-type 1 and Zollinger-Ellison syndrome: long-term outcome of a more virulent form of HPT.

Authors:  Jeffrey A Norton; David J Venzon; Marc J Berna; H R Alexander; Douglas L Fraker; Stephen K Libutti; Stephen J Marx; Fathia Gibril; Robert T Jensen
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

Review 9.  Hereditary hyperparathyroidism--a consensus report of the European Society of Endocrine Surgeons (ESES).

Authors:  Maurizio Iacobone; Bruno Carnaille; F Fausto Palazzo; Menno Vriens
Journal:  Langenbecks Arch Surg       Date:  2015-10-08       Impact factor: 3.445

10.  Differences between sporadic and MEN related primary hyperparathyroidism; clinical expression, preoperative workup, operative strategy and follow-up.

Authors:  Bas A Twigt; Anouk Scholten; Gerlof D Valk; Inne H M Borel Rinkes; Menno R Vriens
Journal:  Orphanet J Rare Dis       Date:  2013-04-01       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.